Effects of Yinian Jiangya decoction containing serum on cytokines secretion of vascular endothelium of spontaneously hypertensive rats

Chinese Journal of Integrative Medicine

Volumn 16, Issue 4, 2010, Pages 344-347

  Zhao, Yong Hua ^a   Xu, You Hua ^a   Guan, Ying ^a   Xiang, Ping ^a  

^a MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

Author keywords

Cytokine; Endothelial cell; Yinian jiangya decoction

Indexed keywords

CHINESE DRUG; ENDOTHELIN 1; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; YINIAN JIANGYA; CYTOKINE; HERBACEOUS AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CYTOKINE RELEASE; DRUG EFFECT; DRUG MEGADOSE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR ENDOTHELIUM; ANIMAL; CELL FRACTIONATION; ENDOTHELIUM CELL; METABOLISM; SECRETION; TIME;

ANIMALS; CYTOKINES; DRUGS, CHINESE HERBAL; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; MALE; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, INBRED SHR; SUBCELLULAR FRACTIONS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 79952012277     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-010-0524-y     Document Type: Article

References (10)

1. Zhao YH, Liu YD, Huang PD, Xiang P. Effects of clinical treatment and protection on endothelial function of early essential hypertension's patients treated with YNJY soup in southern Guangdong area. China J Tradit Chin Med Pharm (Chin) 2009;24:1149-1152.
2. Zhang YH, Hu Y, Mei H, Wang HF, Guo T, Wei WN. Compared study for three methods to isolate endothelial cells from rat aorta. Chin J Microcirc (Chin) 2007;17:15-16.
3. Hynynen MM, Khalil RA. The vascular endothelin system in hypertension - recent patents and discoveries. Recent Pat Cardiovasc Drug Discov 2006;1:95-108.
4. Spieker LE, Noll G, Ruschitzka FT, Lüscher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 2001;37:1493-505.
5. Giles TD. Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J Clin Hypertens (Greenwich) 2006;8:2-16.
6. Augustyniak RA, Thomas GD, Victor RG, Zhang W. Nitric oxide pathway as new drug targets for refractory hypertension. Curr Pharm Des 2005;11:3307-3315. (Pubitemid 41300780)
7. Siragy HM. Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin- aldosterone system blockers. J Hypertens 2010;28:2-8.
8. Tabak O, Gelisgen R, Uzun H, Kalender B, Balci H, Curgunlu A, et al. Hypertension and hemostatic/fibrinolytic balance disorders. Clin Invest Med 2009;32:E285.
9. Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 2006;19:1293-1299.
10. Ulfhammer E, Ridderstrale W, Andersson M, Karlsson L, Hrafnkelsdóttir T, Jern S. Prolonged cyclic strain impairs the fibrinolytic system in cultured vascular endothelial cells. J Hypertens 2005;23:1551-1557. (Pubitemid 41104827)